Skip to main content
Chongqing Pharscin Pharmaceutical Co., Ltd. logo

Chongqing Pharscin Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002907 ISIN · CNE100003308 LEI · 300300M2F5XMGFAYMA24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2026-01-30 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002907

About Chongqing Pharscin Pharmaceutical Co., Ltd.

https://www.pharscin.com

Chongqing Pharscin Pharmaceutical Co., Ltd. is an integrated enterprise specializing in the research, development, production, and commercialization of chemical drugs and modern traditional Chinese medicine. The company focuses on therapeutic areas such as digestive system health, cardiovascular and cerebrovascular diseases, and hepatobiliary conditions. Its portfolio includes a variety of proprietary formulations and generic medications, notably treatments for chronic liver disease and gastrointestinal disorders. Pharscin maintains advanced manufacturing facilities and a dedicated R&D infrastructure focused on enhancing drug efficacy and delivery systems. The organization emphasizes clinical value and technological innovation to provide comprehensive healthcare solutions across diverse medical sectors.

Recent filings

Filing Released Lang Actions
关于公司产品完成境内生产药品备案的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of domestic production drug filing for a product, including details about the drug, regulatory approval, and impact on the company. It is a short announcement (1302 characters) and does not contain financial statements or detailed financial data. It is not an annual or interim report, earnings release, or any detailed financial or management report. It is a regulatory announcement about product registration and approval status. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-01-30 Chinese
关于公司全资子公司通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the recognition of a wholly-owned subsidiary as a national high-tech enterprise, including details about tax benefits and certification validity. It is a regulatory announcement about a corporate event, not a financial report, earnings release, or management discussion. The document is short (512 characters) and does not contain financial statements or detailed financial data. It is an official disclosure to investors about a corporate status update, fitting best under Regulatory Filings (RNS).
2026-01-14 Chinese
关于公司收到药品再注册批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Chongqing Huashen Pharmaceutical Co., Ltd. regarding the receipt of drug re-registration approval notices from the Chongqing Drug Administration. It details the approval of re-registration for eight pharmaceutical products, including their specifications, approval numbers, and validity periods. The document also discusses the impact on the company and includes references to the approval notices as backup files. There is no financial data, no discussion of financial performance, no management or board changes, no voting results, no earnings information, and no regulatory certifications. The document is a regulatory announcement about drug registration approvals, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into other specific categories.
2026-01-14 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report". It details changes in shareholding percentages and share quantities held by specific shareholders, including information about share reduction, shareholding percentages before and after the change, and plans for future share transactions. The document references compliance with Chinese securities laws and disclosure standards related to equity changes. It is a detailed report on changes in major shareholdings, including disclosures by controlling shareholders and related parties. There is no indication that this is an annual report, earnings release, or any other financial report type. The document is not a mere announcement of a report but contains substantive data on shareholding changes. Therefore, the document fits the category of "Major Shareholding Notification" (Code: MRQ).
2026-01-13 Chinese
关于控股股东及其一致行动人权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding changes in shareholding by the controlling shareholder and related parties. It details the reduction in shareholding percentages, the number of shares held before and after the change, and compliance with relevant securities laws and regulations. The document does not contain financial statements or detailed financial performance data but focuses on shareholding changes and disclosures related to them. This fits the definition of a Major Shareholding Notification (MRQ), which involves notifications of changes in significant share ownership levels.
2026-01-13 Chinese
关于公司特殊医学用途配方食品生产许可证变更的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Chongqing Huashen Pharmaceutical Co., Ltd. regarding a change in their Special Medical Purpose Formula Food Production License. It details the approval of an expanded food category scope by the Chongqing Market Supervision Administration. The document includes specifics about the license, product information, market data, and the impact on the company. It is a regulatory announcement about a license change rather than a financial report, earnings release, or management discussion. The document length is short (1462 characters) and it is clearly an announcement of a regulatory approval/license change. Therefore, it fits best under Regulatory Filings (RNS) as it does not match any other more specific category such as Capital/Financing Update or Legal Proceedings. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory license change.
2025-12-30 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.